Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Fate Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$2.06

+0.09 (+4.57%)

C 54Pipeline Score Fair Value Biotech · Commercial
Market Cap
262.26 M
EPS
-1.09
P/E Ratio
-
Value Trade
17.32 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • Revenue

    1.30 M

  • R&D Expenses

    24.70 M

  • Operating CF

    -30.82 M

  • Total Assets

    284.92 M

  • Total Liabilities

    284.92 M

  • Equity

    179.71 M

  • D/E Ratio

    12,345

20.97 %
Week
61.87 %
1 Month
63.04 %
3 Month
125 %
6 Month
-97.13 %
5 Year
-65.7 %
All Time
Cash Data
Stable

  • Cash Position

    174.82 M

  • Monthly Burn

    10.27 M

  • Runway

    16.1 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
4.70 M
52 Week Range
0.91 - 2.47
% held by Insiders
5.16 %
% held by Institutions
60.84 %
Enterprise Value
164.22 M
Total Shares
116.27 M
Short %
10.82 %
Float Shares
98.83 M
Company Description
HQ: 12278 SCRIPPS SUMMIT DRIVE, SA...
Employees:161
https://www.fatetherapeutics.c...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout example
FT836 Advanced solid tumors
Phase 1
—
Gene Therapies
Oncology
FT836 Advanced solid tumors
Phase 1
—
Gene Therapies
Oncology
FT836 Advanced solid tumors
Phase 1
—
Gene Therapies
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C54
Pipeline Score
$551M
Pipeline Value
Fair Value
Valuation Signal
11
Drugs Scored
2.1x
rNPV / MCap
Top 80%
Micro Cap
(rank 182 of 905)
Percentile Rank
Fate Therapeutics, Inc. carries a moderate pipeline score (54/100), with $5.2B risk-adjusted pipeline value, led by FT825 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
FT825
Small molecule		Advanced Solid TumorPhase 1NCT0624145610% $3.3B RECRUITING 351 STALLED C (49) May 1, 2044HIGH_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
FT819
Systemic Lupus Erythematosus,Lupus Nephritis
Phase 1
2025-10-27
FT819
Systemic Lupus Erythematosus,Lupus Nephritis
Phase 1
2025-10-27
FT819
Systemic Lupus Erythematosus,Lupus Nephritis
Phase 1
2025-10-27
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in FATE
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
FATE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FATE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
FATE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
FATE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
FATE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
2026-08-210 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Fate Therapeutics, Inc. (FATE) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How FATE ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Vasculitis #8 of 16 PHASE 1 FT819 + Fludarabine + Cyclophosphamide + Bendamustine
AZN GSK ABBV
$2.5B 0.69 FOLLOWER
Systemic Lupus Erythematosus #14 of 32 PHASE 2 FT819
BIIB VTRS BMY
$2.78B 0.69 FOLLOWER
Systemic Sclerosis #14 of 21 PHASE 1 FT819 + Fludarabine + Cyclophosphamide + Bendamustine
AZN BMY MRK
$2.68B 0.69 FOLLOWER
Lupus Nephritis #14 of 17 PHASE 2 FT819
NVS VTRS AZN
$1.2B 0 FOLLOWER
Endometrial Cancer #36 of 48 PHASE 1 FT836 + Paclitaxel + Cetuximab + Trastuzumab
MRK AZN GILD
$31.09B 0.66 FOLLOWER
Head and Neck Cancer #41 of 63 PHASE 1 FT836 + Paclitaxel + Cetuximab + Trastuzumab
AZN GSK MRK
$10.2B 0.66 FOLLOWER
Ovarian Cancer #46 of 61 PHASE 1 FT836 + Paclitaxel + Cetuximab + Trastuzumab
MRK AZN LLY
$4.0B 0.66 FOLLOWER
Leukemia #52 of 64 PHASE 1 FT819 + Cyclophosphamide + Fludarabine + IL-2 + Bendamustine
AMGN LLY AZN
$4.28B 0.52 FOLLOWER
Breast Cancer #54 of 94 PHASE 1 FT836 + Paclitaxel + Cetuximab + Trastuzumab
MRK AZN GILD
$10.85B 0.66 FOLLOWER
Colorectal Cancer #56 of 82 PHASE 1 FT836 + Paclitaxel + Cetuximab + Trastuzumab
ABBV BMY MRK
$7.68B 0.66 FOLLOWER
Lymphoma #58 of 69 PHASE 1 FT819 + Cyclophosphamide + Fludarabine + IL-2 + Bendamustine
REGN LLY MRK
$8.52B 0.52 FOLLOWER
Non-Small Cell Lung Cancer #67 of 88 PHASE 1 FT836 + Paclitaxel + Cetuximab + Trastuzumab
MRK AMGN AZN
$28.1B 0.66 FOLLOWER